Could you share your outlook for growth and how Cipla plans to address any challenges? Our focus remains on a strong pipeline of products to bridge any potential revenue gaps. For instance, a ...

While all eyes are on the Indian industry – known for its ability to produce generic drugs at a fraction of the cost – to ...

Brand-heavy companies such as Mankind Pharma, Sun Pharma, Torrent Pharmaceuticals and Eris Lifesciences are expected to ...

Cipla results - Read all the latest news headline updates on Cipla results. Get all the Cipla results breaking news updates, videos, photostories and more at Business Standard.

Indian generic drugmaker Lupin reported a bigger-than-expected rise in second-quarter profit on Thursday, driven by strong demand for its respiratory and diabetes management drugs.

Global Inhalable Drugs market size is expected to reach US$ 56.68 Bn by 2030, from US$ 34.86 Bn in 2023, exhibiting a CAGR of 7.2% during the forecast period. Mr. Shah Coherent Market Insights Pvt.

Indian drugmaker Alembic Pharmaceuticals reported a smaller-than-expected rise in second-quarter profit on Thursday, hurt by a slowdown in the U.S. market amid pricing pressure. The ...

Welcome to the Cipla Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market. Stay on top of the game with our comprehensive coverage, ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

India's J B Chemicals & Pharmaceuticals reported a rise in second-quarter profit on Wednesday, helped by higher domestic demand for its gastrointestinal and cardiovascular drugs.

The Cigna Group posted strong Q3 2024 results, yet CI stock is down nearly 20% from its 52-week high. See why this may ...

Although it's about four times the price of table sugar, allulose is considered 70% as sweet and nearly calorie-free. However, health experts caution that further research is needed on its long-term ...